Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on the shelf

The future of BCMA cell therapy is allogenic, it seems, as Poseida has decided to back away from work on its autologous candidate.

Autologous chimeric antigen receptor (CAR) T cells, i.e., ones derived from the patient, have no doubt helped changed the face of how we treat certain blood cancers, but a new wind is blowing and caused Poseida a casualty in its pipeline.